Meredith Wetzel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Meredith Wetzel has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
- Elana Judith Fertig
Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD, USA
40 shared publications - Elizabeth M. Jaffee
Johns Hopkins Convergence Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland
39 shared publications - Won Jin Ho
Johns Hopkins University 4 Department of Oncology, School of Medicine Baltimore, Maryland
31 shared publications - Janelle M. Montagne
Johns Hopkins Convergence Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA
30 shared publications - Ludmila Danilova
Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD, USA
30 shared publications - Robert A. Anders
Johns Hopkins University 2 Department of Pathology Baltimore, Maryland
30 shared publications
Latest Publications
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Clinical, Genomic, and Spatial Transcriptomic Features of Pancreatic Adenosquamous Carcinoma Support Subtype-Specific Therapeutic Strategies
Survival outcomes in ASQ versus PDAC
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Clinical, Genomic, and Spatial Transcriptomic Features of Pancreatic Adenosquamous Carcinoma Support Subtype-Specific Therapeutic Strategies
Survival outcomes in ASQ versus PDAC
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Clinical, Genomic, and Spatial Transcriptomic Features of Pancreatic Adenosquamous Carcinoma Support Subtype-Specific Therapeutic Strategies
Pathologic and molecular features
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Clinical, Genomic, and Spatial Transcriptomic Features of Pancreatic Adenosquamous Carcinoma Support Subtype-Specific Therapeutic Strategies
Pathologic and molecular features
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Clinical, Genomic, and Spatial Transcriptomic Features of Pancreatic Adenosquamous Carcinoma Support Subtype-Specific Therapeutic Strategies
Neoadjuvant chemotherapy regimens in spatial transcriptomics cohort
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Clinical, Genomic, and Spatial Transcriptomic Features of Pancreatic Adenosquamous Carcinoma Support Subtype-Specific Therapeutic Strategies
Neoadjuvant chemotherapy regimens in spatial transcriptomics cohort
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Clinical, Genomic, and Spatial Transcriptomic Features of Pancreatic Adenosquamous Carcinoma Support Subtype-Specific Therapeutic Strategies
Full statistics for pathway enrichment analysis of ASQ versus PDAC
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Clinical, Genomic, and Spatial Transcriptomic Features of Pancreatic Adenosquamous Carcinoma Support Subtype-Specific Therapeutic Strategies
Full statistics for pathway enrichment analysis of ASQ versus PDAC
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Clinical, Genomic, and Spatial Transcriptomic Features of Pancreatic Adenosquamous Carcinoma Support Subtype-Specific Therapeutic Strategies
Tissue sampling sites in FoundationOne cohort
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Clinical, Genomic, and Spatial Transcriptomic Features of Pancreatic Adenosquamous Carcinoma Support Subtype-Specific Therapeutic Strategies
Tissue sampling sites in FoundationOne cohort
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Clinical, Genomic, and Spatial Transcriptomic Features of Pancreatic Adenosquamous Carcinoma Support Subtype-Specific Therapeutic Strategies
Full statistics for differential gene expression analysis of ASQ versus PDAC
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Clinical, Genomic, and Spatial Transcriptomic Features of Pancreatic Adenosquamous Carcinoma Support Subtype-Specific Therapeutic Strategies
Full statistics for differential gene expression analysis of ASQ versus PDAC
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Clinical, Genomic, and Spatial Transcriptomic Features of Pancreatic Adenosquamous Carcinoma Support Subtype-Specific Therapeutic Strategies
Full statistics for differential gene expression analysis of squamous versus glandular regions in ASQ
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Clinical, Genomic, and Spatial Transcriptomic Features of Pancreatic Adenosquamous Carcinoma Support Subtype-Specific Therapeutic Strategies
Full statistics for differential gene expression analysis of squamous versus glandular regions in ASQ
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from Clinical, Genomic, and Spatial Transcriptomic Features of Pancreatic Adenosquamous Carcinoma Support Subtype-Specific Therapeutic Strategies
Full statistics for pathway enrichment analysis of squamous versus glandular regions in ASQ
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from Clinical, Genomic, and Spatial Transcriptomic Features of Pancreatic Adenosquamous Carcinoma Support Subtype-Specific Therapeutic Strategies
Full statistics for pathway enrichment analysis of squamous versus glandular regions in ASQ
- 14 August 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (20) , 4683-4697
Clinical, Genomic, and Spatial Transcriptomic Features of Pancreatic Adenosquamous Carcinoma Support Subtype-Specific Therapeutic Strategies
Purpose: Pancreatic adenosquamous carcinoma (ASQ) is a rare variant with poorly defined clinical and molecular features compared with conventional pancreatic ductal adenocarcinoma (PDAC). This study aimed to characterize the clinical outcomes, genomic landscape, and spatial transcriptomic architecture of ASQ. Experimental Design: We retrospectively evaluated the clinicopathologic features, treatment patterns, and survival of patients with ASQ treated at Johns Hopkins from 2013 to 2023 (n = 178). Genomic landscapes of ASQ (n = 244) versus PDAC (n = 29,021) were compared using the FoundationCore database. Surgically resected ASQ tumors (n = 11 from eight patients) were analyzed using Visium spatial transcriptomics with a comparator PDAC dataset (n = 4). Results: Patients with ASQ had poor outcomes in both resected and advanced disease. FoundationCore analysis revealed similar KRAS mutation frequency, higher MTAP loss, and enrichment of low-frequency immune biomarkers (microsatellite instability–high, PD-L1+, TMB ≥10 muts/Mb) in ASQ compared with PDAC. Spatial transcriptomics revealed broadly similar immune cell proportions across subtypes, with higher regulatory T-cell abundance observed in ASQ in the context of sparse detection in PDAC. Differences in spatial co-localization patterns of immune populations were observed between ASQ and PDAC, whereas distance analyses within ASQ showed immune infiltrates closest to squamous regions and farthest from glandular regions. Furthermore, ASQ showed increased squamous/basal lineage expression compared with PDAC, with intratumoral squamous regions enriched for epithelial–mesenchymal transition, apical junction, inflammatory, and stress response pathways relative to the glandular niche. Conclusions: Despite shared genomic drivers with PDAC, ASQ exhibits transcriptionally distinct features with spatially organized tumor and immune heterogeneity, supporting the need for subtype-specific therapeutic strategies.
- 14 August 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (20) , 4683-4697
Clinical, Genomic, and Spatial Transcriptomic Features of Pancreatic Adenosquamous Carcinoma Support Subtype-Specific Therapeutic Strategies
Purpose: Pancreatic adenosquamous carcinoma (ASQ) is a rare variant with poorly defined clinical and molecular features compared with conventional pancreatic ductal adenocarcinoma (PDAC). This study aimed to characterize the clinical outcomes, genomic landscape, and spatial transcriptomic architecture of ASQ. Experimental Design: We retrospectively evaluated the clinicopathologic features, treatment patterns, and survival of patients with ASQ treated at Johns Hopkins from 2013 to 2023 (n = 178). Genomic landscapes of ASQ (n = 244) versus PDAC (n = 29,021) were compared using the FoundationCore database. Surgically resected ASQ tumors (n = 11 from eight patients) were analyzed using Visium spatial transcriptomics with a comparator PDAC dataset (n = 4). Results: Patients with ASQ had poor outcomes in both resected and advanced disease. FoundationCore analysis revealed similar KRAS mutation frequency, higher MTAP loss, and enrichment of low-frequency immune biomarkers (microsatellite instability–high, PD-L1+, TMB ≥10 muts/Mb) in ASQ compared with PDAC. Spatial transcriptomics revealed broadly similar immune cell proportions across subtypes, with higher regulatory T-cell abundance observed in ASQ in the context of sparse detection in PDAC. Differences in spatial co-localization patterns of immune populations were observed between ASQ and PDAC, whereas distance analyses within ASQ showed immune infiltrates closest to squamous regions and farthest from glandular regions. Furthermore, ASQ showed increased squamous/basal lineage expression compared with PDAC, with intratumoral squamous regions enriched for epithelial–mesenchymal transition, apical junction, inflammatory, and stress response pathways relative to the glandular niche. Conclusions: Despite shared genomic drivers with PDAC, ASQ exhibits transcriptionally distinct features with spatially organized tumor and immune heterogeneity, supporting the need for subtype-specific therapeutic strategies.
- Open Access
Deep Learning Enabled 3D Multi-Omic Analysis Reveals Molecular Signatures of Heterogeneous Response to Chemotherapy in Pancreatic Cancer
Resistance to systemic therapy is a major unmet challenge in pancreatic cancer. To identify potential mechanisms of resistance, we developed a novel 3D pipeline in clinical samples that uses deep learning to classify sensitive and persistent tumor cell populations based on morphological features, enabling subsequent molecular characterization of intratumoral heterogeneity. We applied this automated 3D pipeline to a cohort of human pancreatic cancer samples treated with neoadjuvant chemotherapy, identifying heterogeneity in response to therapy both between and within tumors. Application of spatial proteomics to these sensitive and persistent regions identified enhanced epithelial-to-mesenchymal transition and non-classical cell states in persistent cells, confirming our morphological classification. Integration of spatial transcriptomics in multiple pancreatic cancer cohorts associated fibroblast-cancer crosstalk via syndecans with resistance to cytotoxic therapy. Our validated 3D multi-omic pipeline is now poised for application to clinical trials, enabling discovery of resistance mechanisms and design of new therapeutic combinations to circumvent resistance. Statement of significance: We developed a novel 3D multi-omic pipeline to identify mechanisms of resistance to chemotherapy in clinical samples. This approach associated fibroblast-cancer crosstalk via syndecans with resistance to cytotoxic therapy and is poised for broader application in neoadjuvant clinical trials.
Open AccessDeep Learning Enabled 3D Multi-Omic Analysis Reveals Molecular Signatures of Heterogeneous Response to Chemotherapy in Pancreatic Cancer
Resistance to systemic therapy is a major unmet challenge in pancreatic cancer. To identify potential mechanisms of resistance, we developed a novel 3D pipeline in clinical samples that uses deep learning to classify sensitive and persistent tumor cell populations based on morphological features, enabling subsequent molecular characterization of intratumoral heterogeneity. We applied this automated 3D pipeline to a cohort of human pancreatic cancer samples treated with neoadjuvant chemotherapy, identifying heterogeneity in response to therapy both between and within tumors. Application of spatial proteomics to these sensitive and persistent regions identified enhanced epithelial-to-mesenchymal transition and non-classical cell states in persistent cells, confirming our morphological classification. Integration of spatial transcriptomics in multiple pancreatic cancer cohorts associated fibroblast-cancer crosstalk via syndecans with resistance to cytotoxic therapy. Our validated 3D multi-omic pipeline is now poised for application to clinical trials, enabling discovery of resistance mechanisms and design of new therapeutic combinations to circumvent resistance. Statement of significance: We developed a novel 3D multi-omic pipeline to identify mechanisms of resistance to chemotherapy in clinical samples. This approach associated fibroblast-cancer crosstalk via syndecans with resistance to cytotoxic therapy and is poised for broader application in neoadjuvant clinical trials.